Iterum Therap | 10-Q: FY2025 Q3 Revenue: USD 390 K

LB filings
2025.11.14 12:34
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 390 K.

EPS: As of FY2025 Q3, the actual value is USD -0.2, missing the estimate of USD -0.09.

EBIT: As of FY2025 Q3, the actual value is USD -7.29 M.

Segment Revenue

  • Product Revenue, net: $390,000 for the three months ended September 30, 2025, compared to $0 for the same period in 2024. For the nine months ended September 30, 2025, product revenue was $390,000, compared to $0 in 2024.

Operational Metrics

  • Operating Loss: For the three months ended September 30, 2025, operating loss was -$7,731,000, compared to -$4,887,000 for the same period in 2024. For the nine months ended September 30, 2025, operating loss was -$16,970,000, compared to -$15,026,000 in 2024.
  • Net Loss: For the three months ended September 30, 2025, net loss was -$8,979,000, compared to -$6,094,000 for the same period in 2024. For the nine months ended September 30, 2025, net loss was -$20,379,000, compared to -$18,192,000 in 2024.

Cash Flow

  • Net Cash Used in Operating Activities: -$15,258,000 for the nine months ended September 30, 2025, compared to -$22,514,000 for the same period in 2024.
  • Net Cash Provided by Financing Activities: $2,164,000 for the nine months ended September 30, 2025, compared to $12,814,000 for the same period in 2024.

Unique Metrics

  • Amortization of Intangible Asset: $1,036,000 for the nine months ended September 30, 2025, compared to $0 for the same period in 2024.

Future Outlook and Strategy

  • Core Business Focus: Iterum Therapeutics plc is focused on maximizing the commercial potential of ORLYNVAH™ in the U.S. and seeking marketing approval for other product candidates. The company expects modest sales of ORLYNVAH™ in 2025 during the early stages of commercialization efforts.
  • Non-Core Business: The company continues to engage in business development discussions with other companies to sell, license, or otherwise dispose of its rights to sulopenem.
  • Priority: The company is heavily dependent on the success of the commercial launch of ORLYNVAH™ in the United States and any failure to successfully commercialize ORLYNVAH™ will materially harm its business.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.